# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Kennedy disease

Spinobulbar muscular atrophy (SBMA)Bulbospinal amyotrophy, X-Linked
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 28 results.
Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)"
Status: Recruiting
Last Changed: Aug 13, 2018
First Received: Jun 13, 2018
Disease(s): Spinal and Bulbar Muscular Atrophy
Intervention(s): Leuprorelin Acetate
Locations: Takeda Selected Site, Tokyo, Japan
Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive Glioblastoma
Status: Recruiting
Last Changed: Sep 18, 2019
First Received: Jul 25, 2018
Disease(s): Solid Tumor, Androgen Receptor Gene Overexpression
Intervention(s): SEVI-D (Seviteronel in combination with dexamthasone)
Locations: St Vincent's Hospital, Darlinghurst, New South Wales, Australia
Study of Hepatic Function in Patients With Spinal and Bulbar Muscular Atrophy
Status: Recruiting
Last Changed: Nov 15, 2019
First Received: Apr 28, 2014
Disease(s): Spinal and Bulbar Muscular Atrophy, Motor Neuron Disease
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Study on Androgen Receptor and Triple Negative Breast Cancer
Status: Recruiting
Last Changed: Aug 26, 2019
First Received: Dec 26, 2017
Disease(s): Breast Cancer Female, Triple Negative and Androgen Receptor Positive
Intervention(s): Darolutamide, Capecitabine
Locations: Centre François Baclesse, Caen, France
Acoustic and Perceptual Markers of Dysarthria in Amyotrophic Lateral Sclerosis (ALS)
Status: Recruiting
Last Changed: Aug 14, 2018
First Received: Jun 18, 2018
Disease(s): Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, Kennedy's Disease
Locations: APHP - Hôpital Pitié-Salpêtriere, Paris, France
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
Status: Recruiting
Last Changed: Jun 07, 2019
First Received: Feb 24, 2016
Disease(s): Androgen Receptor Positive, Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Intervention(s): Axillary Lymph Node Dissection, Enzalutamide, Laboratory Biomarker Analysis, Lymph Node Biopsy, Paclitaxel, Therapeutic Conventional Surgery
Locations: M D Anderson Cancer Center, Houston, Texas, United States
Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer
Status: Recruiting
Last Changed: Sep 18, 2019
First Received: Jul 02, 2017
Disease(s): Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Androgen Receptor Positive, Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Metastatic Breast Carcinoma, Progesterone Receptor Negative, Progesterone Receptor Positive, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, PTEN Positive, Recurrent Breast Carcinoma, Refractory Breast Carcinoma, Triple-Negative Breast Carcinoma
Intervention(s): Alpelisib, Enzalutamide
Locations: M D Anderson Cancer Center, Houston, Texas, United States
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
Status: Recruiting
Last Changed: Nov 22, 2019
First Received: Jan 11, 2017
Disease(s): Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Hormone-Refractory Prostate Cancer
Intervention(s): GnRH agonist/antagonist, Prednisone, Abiraterone Acetate, Enzalutamide
Locations: City of Hope Comprehensive Cancer Center, Los Angeles, California, United States
Northwestern University, Chicago, Illinois, United States
University of Minnesota: Masonic Cancer Center, Minneapolis, Minnesota, United States
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression
Status: Recruiting
Last Changed: Jun 06, 2019
First Received: Apr 25, 2018
Disease(s): Prostate Cancer
Intervention(s): Flutamide, Placebo
Locations: SKCCC at Johns Hopkins, Baltimore, Maryland, United States
Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
Status: Recruiting
Last Changed: Aug 15, 2019
First Received: May 08, 2019
Disease(s): Salivary Gland Carcinoma
Intervention(s): Goserelin Acetate, Pembrolizumab
Locations: University of Minnesota: Masonic Cancer Center, Minneapolis, Minnesota, United States